In the traditional phase 1 clinical trial design, the mainstream dose climbing test design method is rule-based 3 + 3 design, which is widely used in the market for the reason that its high safety. However, this method also has many defects.

On February 22, 2019, the annual meeting of China New Drug Research and Development Association (SDDA) was held in Shanghai. Academician Wen Yumei and Chief Science Officer of Xinda, Kerry L. Blanchar, were invited to give a brilliant report at the meeting. It attracted nearly 150 participants from drug research and development and investment institutions, and discussed issues related to drug innovation, cutting-edge technology and so on.